Pfizer's RSV vaccine displays possible to offer protection to high-risk adults ages 18-59, widening imaginable use
Respiration syncytial virus – viral vaccine below researchHailshadow | Istock | Getty ImagesA vaccine from Pfizer confirmed the possible to offer protection to adults ages 18 to 59 who’re at greater threat